Immunology Core

免疫学核心的总体目标是提供必要的基础设施，以确定 对感染性病原体(病毒、细菌及其产物)的先天和适应性免疫反应。会的 还为潜在的候选疫苗提供标准化测试，包括在 生物分子生产综合服务中心为核心，与波士顿大学之间的服务促进者 医学中心转基因核心和Neidl，以提供转基因和突变小鼠 调查人员。这些小鼠将被用于表征先天和获得性免疫反应。 在整个动物环境中模拟病原体。为了监测先天和获得性免疫反应 在体内和体外，核心将提供以下服务：1)进行基本的细胞计数和 使用磁分离为人类、非人灵长类和小动物细胞提供分离服务，如 以及用流式细胞仪鉴定高包裹性(BLS-4)中的细胞亚群；2)阐明细胞因子谱 用流式细胞仪检测反应细胞，用BioPlex测定血清和培养物中细胞因子的产生 分析；3)用酶联免疫吸附试验鉴定体液抗体反应，用ELISPOT进行抗体计数 细胞的产生和中和抗体的自动空斑和菌落计数鉴定 4)根据需要提供其他免疫学检测的咨询服务，如 监测受感染人群的细胞毒性T细胞和自然杀伤细胞；以及5)监测 与之相互作用或感染的人和其他动物细胞的表面抗原表达 由多种病原体引起，包括MHC、共刺激分子、细胞因子和趋化因子受体等。 免疫学核心主任和/或副主任将与皮埃尔·S项目协商开发 根据需要使用特定的ELISA法测定病毒/微生物载量的分析方法，并将开发 病毒和细菌种群表型鉴定的必要试剂。

The overall goal of the Immunology Core is to provide the infrastructure necessary for the characterization of the innate and adaptive immune responses to infectious agents (viruses, bacteria and their products). It will also provide standardized testing for potential vaccine candidates, including proteins produced within the Biomolecule Production integrated service center core, and serve facilitator between the Boston University Medical Center Transgenic Core and the NEIDL in order to provide transgenic and mutant mice for investigators. These mice will be used for the characterization of the innate and adaptive immune responses to model pathogens in the whole animal context. In order to monitor innate and adaptive immune responses in vivo and in vitro, the core will provide the following services: 1) perform basic cell enumeration and separation services for human, non-human primate and small animal cells using magnetic separation, as well as cell subset identification by flow cytometry in high containment (BLS-4); 2) elucidate cytokine profiles of responding cells by flow cytometry, and cytokine production measured in serum and in culture by BioPlex analysis; 3) characterize humoral antibody responses by ELISA, perform ELISPOT for enumerating antibody producing cells, and identification of neutralizing antibodies using automated plaque and colony counting assays; 4) provide consultation services for developing other immunological assays as needed, such as monitoring of cytotoxic T cells and natural killer cells to infected populations; and 5) monitor changes in surface antigen expression in both human and other animal cells that have interacted with or been infected by various pathogens, including MHC, costimulatory molecules, cytokine and chemokine receptors, etc. The Director and/or Associate Director of the Immunology Core will consult with the project PI¿s to develop assays as needed for measuring viral/microbial loads using specific ELISA assays and will develop necessary reagents for the phenotyping of viral and bacterial stocks.